-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Opus Genetics, Raises Price Target to $11

Benzinga·11/11/2026 15:24:08
Listen to the news
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $9 to $11.